Monday, 22 Jan 2018

You are here

2017 Update of Treat to Target Recommendations for SpA/PsA

A 2017 international committee of experts met to assess and revise its earlier 2012 recommendations regarding treating to target in patients with psoriatic arthritis (PsA) and axial peripheral spondyloarthritis (SpA). 

In August 2016, the 34 member task force committee met and included 4 patients, 1 (non-MD) health professional, 2 dermatologists and 28 rheumatologists (6 from North America, 22 from Europe). They authored 5 overarching principles and 11 recommendations, some included in the original and others being new recommendations. 

Overarching Principles

  • The treatment target must be based on a shared decision between patient and rheumatologist.  The patients felt strongly about the need for physicians to adhere to evidence-based therapies and to educate patients on the importance of such therapies versus unproven approaches.
  • Treatment to target by measuring disease activity, and adjusting therapy accordingly, improves outcomes. This is based on data in PsA from the TICOPA; but no T2T study has been performed in axial SpA, (it was deemed that such an approach could also improve outcomes in axial SpA).
  • SpA and PsA are multifaceted systemic diseases; the management of musculoskeletal and extra-articular manifestations should be coordinated, as needed, between the rheumatologist and other specialists.
  • The goals of treating the patient with axial SpA or PsA are to optimise long-term health-related quality of life and social participation through control of signs and symptoms, prevention of structural damage, normalisation or preservation of function, avoidance of toxicities and minimisation of comorbidities.
  • Abrogation of inflammation is important to achieve these goals.

Consensus Recommendations

  1. The treatment target should be clinical remission/inactive disease of musculoskeletal (arthritis, dactylitis, enthesitis, axial disease) and extra-articular manifestations.
  2. The treatment target should be individualised based on the current clinical manifestations of the disease; the treatment modality should be considered when defining the time required to reach the target.
  3. Clinical remission/inactive disease is defined as the absence of clinical and laboratory evidence of significant disease activity.
  4. Low/minimal disease activity may be an alternative treatment target. 
  5. Disease activity should be measured on the basis of clinical signs and symptoms, and acute phase reactants
  6. Validated measures of musculoskeletal disease activity and assessment of cutaneous and/or other relevant extra-articular manifestations should be used in clinical practice to define the target and to guide treatment decisions; the frequency of the measurements depends on the level of disease activity.
  7. In axial SpA, ASDAS is a preferred measure and in PsA DAP SA or MDA should be considered to define the target.
  8. The choice of the target and of the disease activity measure should take comorbidities, patient factors and drug-related risks into account. 
  9. In addition to clinical and laboratory measures, imaging results may be considered in clinical management.
  10. Once the target is achieved, it should ideally be maintained throughout the course of the disease.
  11. The patient should be appropriately informed and involved in the discussions about the treatment target, and the risks and benefits of the strategy planned to reach this target. 
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Cardiac Disturbances Increased in Spondyloarthritis

A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.

FDA Approves Xeljanz for Use in Psoriatic Arthritis

Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has approved Xeljanz (tofacitinibi) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).